The CFP macromolecule attenuates senescent liver sinusoidal endothelial cell-driven activation of hepatic stellate

Guanjie Liu1, Qingyang Leng1, Shengda Tian1

  • 1Department of Endocrinology, Seventh People's Hospital of Shanghai University of Traditional Chinese Medicine, Shanghai, China.

Insights

Properdin (CFP) is identified as a novel biomarker for liver fibrosis in metabolic-associated steatohepatitis (MASH). Reduced CFP in liver sinusoidal endothelial cells (LSECs) correlates with fibrosis progression and promotes TGF-β1 release, exacerbating liver damage.

Area of Science:

  • Hepatology
  • Cellular Biology
  • Biomarker Discovery

Background:

  • Metabolic-associated steatohepatitis (MASH) fibrosis is a major cause of mortality.
  • Cellular senescence drives MASH-related liver fibrosis, but mechanisms are unclear.

Purpose of the Study:

  • Identify novel senescence-associated biomarkers for MASH fibrosis.
  • Elucidate the role of CFP in MASH-associated liver fibrosis.

Main Methods:

  • Integrated analysis of clinical MASH data and single-cell senescence profiles.
  • Weighted gene coexpression network analysis (WGCNA) and machine learning.
  • In vivo MASH-fibrosis mouse model and in vitro senescent LSEC experiments.

Main Results:

  • Properdin (CFP) identified as a senescence marker highly expressed in LSECs, downregulated in MASH fibrosis.
  • Reduced CFP in MASH-fibrosis LSECs correlated with decreased LYVE1 colocalization.
  • Senescent LSECs promoted TGF-β1 release, driving LX-2 cell proliferation and fibrosis.
  • CFP knockdown exacerbated senescence and TGF-β1 secretion; CFP overexpression alleviated these effects.

Conclusions:

  • CFP is a key regulator of cellular senescence and fibrosis in MASH.
  • CFP represents a potential therapeutic target for MASH-associated liver fibrosis.